Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2

di Arbini, A A, Guerra, F, Greco, M, Marra, E, Gandee, L, Xiao, G, Lotan, Y, Gasparre, G, Hsieh, J-T, Moro, L
Pubblicazione 2013

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder

di Xylinas, E, Kent, M, Kluth, L, Pycha, A, Comploj, E, Svatek, R S, Lotan, Y, Trinh, Q-D, Karakiewicz, P I, Holmang, S, Scherr, D S, Zerbib, M, Vickers, A J, Shariat, S F
Pubblicazione 2013

Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment

di Kluth, L A, Abdollah, F, Xylinas, E, Rieken, M, Fajkovic, H, Seitz, C, Sun, M, Karakiewicz, P I, Schramek, P, Herman, M P, Becker, A, Hansen, J, Ehdaie, B, Loidl, W, Pummer, K, Lee, R K, Lotan, Y, Scherr, D S, Seiler, D, Ahyai, S A, Chun, F K-H, Graefen, M, Tewari, A, Nonis, A, Bachmann, A, Montorsi, F, Gönen, M, Briganti, A, Shariat, S F
Pubblicazione 2014

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment

di Pouessel, D., Neuzillet, Y., Mertens, L. S., van der Heijden, M. S., de Jong, J., Sanders, J., Peters, D., Leroy, K., Manceau, A., Maille, P., Soyeux, P., Moktefi, A., Semprez, F., Vordos, D., de la Taille, A., Hurst, C. D., Tomlinson, D. C., Harnden, P., Bostrom, P. J., Mirtti, T., Horenblas, S., Loriot, Y., Houédé, N., Chevreau, C., Beuzeboc, P., Shariat, S. F., Sagalowsky, A. I., Ashfaq, R., Burger, M., Jewett, M. A. S., Zlotta, A. R., Broeks, A., Bapat, B., Knowles, M. A., Lotan, Y., van der Kwast, T. H., Culine, S., Allory, Y., van Rhijn, B. W. G.
Pubblicato in Ann Oncol (2016)